US 10,376,300 B2
Methods and devices to treat nasal airways
Scott J. Wolf, Menlo Park, CA (US); and Andrew Frazier, Sunnyvale, CA (US)
Assigned to AERIN MEDICAL, INC., Austin, TX (US)
Filed by AERIN MEDICAL, INC., Sunnyvale, CA (US)
Filed on Jan. 24, 2019, as Appl. No. 16/256,077.
Application 16/256,077 is a continuation of application No. 15/903,319, filed on Feb. 23, 2018.
Application 15/903,319 is a continuation of application No. 15/480,575, filed on Apr. 6, 2017, granted, now 10,028,780, issued on Jul. 24, 2018.
Application 15/480,575 is a continuation of application No. 15/380,812, filed on Dec. 15, 2016, granted, now 9,913,682, issued on Aug. 13, 2018.
Application 15/380,812 is a continuation of application No. 14/963,719, filed on Dec. 9, 2015, granted, now 9,526,571, issued on Dec. 27, 2016.
Application 14/963,719 is a continuation of application No. 13/495,879, filed on Jun. 13, 2012, granted, now 9,237,924, issued on Jan. 19, 2016.
Claims priority of provisional application 61/603,864, filed on Feb. 27, 2012.
Claims priority of provisional application 61/496,930, filed on Jun. 14, 2011.
Prior Publication US 2019/0151005 A1, May 23, 2019
Int. Cl. A61B 18/02 (2006.01); A61B 18/14 (2006.01); A61B 18/16 (2006.01); A61B 18/18 (2006.01); A61B 18/20 (2006.01); A61F 5/08 (2006.01); A61B 5/01 (2006.01); A61B 18/06 (2006.01); A61B 18/08 (2006.01); A61B 18/12 (2006.01); A61F 5/56 (2006.01); A61N 5/02 (2006.01); A61N 5/06 (2006.01); A61B 17/32 (2006.01); A61B 18/00 (2006.01); A61B 17/24 (2006.01)
CPC A61B 18/02 (2013.01) [A61B 5/01 (2013.01); A61B 18/06 (2013.01); A61B 18/085 (2013.01); A61B 18/1206 (2013.01); A61B 18/14 (2013.01); A61B 18/1442 (2013.01); A61B 18/1445 (2013.01); A61B 18/1477 (2013.01); A61B 18/1485 (2013.01); A61B 18/16 (2013.01); A61B 18/1815 (2013.01); A61B 18/20 (2013.01); A61F 5/08 (2013.01); A61F 5/56 (2013.01); A61N 5/025 (2013.01); A61N 5/0603 (2013.01); A61N 5/0625 (2013.01); A61B 17/320068 (2013.01); A61B 2017/248 (2013.01); A61B 2017/32007 (2017.08); A61B 2017/320069 (2017.08); A61B 2018/00005 (2013.01); A61B 2018/0016 (2013.01); A61B 2018/0022 (2013.01); A61B 2018/00023 (2013.01); A61B 2018/00178 (2013.01); A61B 2018/00327 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00595 (2013.01); A61B 2018/00642 (2013.01); A61B 2018/00702 (2013.01); A61B 2018/00708 (2013.01); A61B 2018/00791 (2013.01); A61B 2018/00821 (2013.01); A61B 2018/00875 (2013.01); A61B 2018/00886 (2013.01); A61B 2018/00922 (2013.01); A61B 2018/00982 (2013.01); A61B 2018/0212 (2013.01); A61B 2018/0225 (2013.01); A61B 2018/0262 (2013.01); A61B 2018/126 (2013.01); A61B 2018/1253 (2013.01); A61B 2018/143 (2013.01); A61B 2018/1425 (2013.01); A61B 2018/1807 (2013.01); A61B 2018/1861 (2013.01); F04C 2270/041 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A method for deactivating tissue in a nasal airway in a patient, the method comprising:
inserting a cryotherapy balloon of a nasal airway treatment device through a nostril of the patient in an uninflated configuration;
inflating the cryotherapy balloon by circulating a liquid into an interior of the cryotherapy balloon to contact the cryotherapy balloon with nasal mucosa lining the nasal airway;
removing energy from submucosal tissue underlying the nasal mucosa by maintaining the cryotherapy balloon in an inflated configuration and continuing to circulate the liquid through the interior of the cryotherapy balloon to deactivate the submucosal tissue underlying the nasal mucosa;
removing the liquid from the interior of cryotherapy balloon; and
removing the cryotherapy balloon from the nasal airway.